Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEM103 + Aflibercept in nAMD
NCT04684394Phase 2Terminated
- Sponsor
- Gemini Therapeutics
- Start
- Dec 2020
- Primary completion
- Jan 2022
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of GEM103 in neovascular age-related macular degeneration (NVAMD), sponsored by Gemini Therapeutics. Started Dec 2020; status: terminated.
02
Drugs
GEM103
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04684394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04684394.